Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Equity Ratio (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Equity Ratio for 6 consecutive years, with 0.04 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 138.94% year-over-year to 0.04, compared with a TTM value of 0.04 through Dec 2025, up 138.94%, and an annual FY2025 reading of 0.04, up 138.94% over the prior year.
  • Equity Ratio was 0.04 for Q4 2025 at Xeris Biopharma Holdings, up from 0.0 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.31 in Q4 2021 and bottomed at 0.11 in Q1 2025.
  • Average Equity Ratio over 5 years is 0.05, with a median of 0.0 recorded in 2023.
  • The sharpest move saw Equity Ratio surged 1068.8% in 2022, then crashed 848.05% in 2024.
  • Year by year, Equity Ratio stood at 0.31 in 2021, then crashed by 58.08% to 0.13 in 2022, then plummeted by 116.03% to 0.02 in 2023, then tumbled by 336.05% to 0.09 in 2024, then surged by 138.94% to 0.04 in 2025.
  • Business Quant data shows Equity Ratio for XERS at 0.04 in Q4 2025, 0.0 in Q3 2025, and 0.06 in Q2 2025.